Evidence map›Paper›PMID 38685990›Full record

ArticleClinical epidemiology2024

Semaglutide (Ozempic

Aurélie Mailhac, Lars Pedersen, Anton Pottegård, Jens Søndergaard, Torben Mogensen, Henrik Toft Sørensen, Reimar W Thomsen

Abstract read
In one paragraph

Article in Clinical epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The unseen risk of Ozempic: NAION and vision damage.Annals of medicine and surgery (2012) · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aurélie MailhacDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-5606-0139
Lars PedersenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Anton PottegårdClinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.ORCID 0000-0001-9314-5679
Jens SøndergaardResearch Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-1629-1864
Torben MogensenDanish Pharmacovigilance Council, Danish Medicines Agency, Copenhagen, Denmark.
Henrik Toft SørensenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-4299-7040
Reimar W ThomsenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-9135-3474

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: A surge in the use of semaglutide injection (Ozempic Patients and Methods: Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic Results: The new user rate of semaglutide (Ozempic Conclusion: The use of semaglutide (Ozempic

Indexed as

anti-obesity drugsdrug utilizationepidemiologyglucose-lowering drugsobesitytype 2 diabetes

Identifiers

PMID38685990
PMCPMC11057509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.